GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SSY Group Ltd (HKSE:02005) » Definitions » Price-to-Owner-Earnings

SSY Group (HKSE:02005) Price-to-Owner-Earnings : 28.06 (As of Apr. 29, 2024)


View and export this data going back to 2005. Start your Free Trial

What is SSY Group Price-to-Owner-Earnings?

As of today (2024-04-29), SSY Group's share price is HK$4.77. SSY Group's Owner Earnings per Share (TTM) ended in Dec. 2023 was HK$0.17. It's Price-to-Owner-Earnings for today is 28.06.


The historical rank and industry rank for SSY Group's Price-to-Owner-Earnings or its related term are showing as below:

HKSE:02005' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 21.92   Med: 48.68   Max: 221.9
Current: 27.58

During the past 13 years, the highest Price-to-Owner-Earnings of SSY Group was 221.90. The lowest was 21.92. And the median was 48.68.


HKSE:02005's Price-to-Owner-Earnings is ranked better than
50.95% of 422 companies
in the Drug Manufacturers industry
Industry Median: 27.82 vs HKSE:02005: 27.58

As of today (2024-04-29), SSY Group's share price is HK$4.77. SSY Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.44. Therefore, SSY Group's PE Ratio for today is 10.77.

As of today (2024-04-29), SSY Group's share price is HK$4.77. SSY Group's EPS without NRI for the trailing twelve months (TTM) ended in was HK$0.44. Therefore, SSY Group's PE Ratio without NRI for today is 10.79.

During the past 13 years, SSY Group's highest PE Ratio without NRI was 40.70. The lowest was 9.21. And the median was 19.20.


SSY Group Price-to-Owner-Earnings Historical Data

The historical data trend for SSY Group's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SSY Group Price-to-Owner-Earnings Chart

SSY Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 48.17 63.48 52.89 43.10 28.55

SSY Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 52.89 - 43.10 - 28.55

Competitive Comparison of SSY Group's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, SSY Group's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SSY Group's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SSY Group's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where SSY Group's Price-to-Owner-Earnings falls into.



SSY Group Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

SSY Group's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=4.77/0.17
=28.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SSY Group  (HKSE:02005) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


SSY Group Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of SSY Group's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


SSY Group (HKSE:02005) Business Description

Traded in Other Exchanges
N/A
Address
Central Plaza, 18 Harbour Road, Rooms 4902-03, 49th Floor, Wanchai, Hong Kong, HKG
SSY Group Ltd is engaged in the research, development, manufacturing and selling of a wide range of pharmaceutical products, which includes finished medicines of mainly intravenous infusion solution and ampoule injection to hospitals and distributors, bulk pharmaceuticals and medical materials. The company has two reportable segments including intravenous infusion solution and others and medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products, followed by medical materials.

SSY Group (HKSE:02005) Headlines

No Headlines